When men with prostate cancer receive androgen-suppressing therapy, lumbar bone mineral density is reduced by about 8%. Small studies have shown heightened risks for osteoporosis, hip and other fractures. Tracey Krupski, University of California, Los Angeles, CA, conducted a review a 5% random sample of Medicare claims data from men with non-metastatic prostate cancer who received GnRH agonists (n=3887) and 7,774 men with the same disease who did not receive them. The objective was to determine which men were the most vulnerable to increased fracture risks on GnRH therapy for prostate cancer.
Go to Previous Page
Go to Next Page